Medical Grand Rounds

Options for preserving fertility in women undergoing gonadotoxic treatment

Laura Detti, MD
Cleveland Clinic Journal of Medicine November 2021, 88 (11) 607-612; DOI: https://doi.org/10.3949/ccjm.88gr.21001

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    Ovarian follicles stained with hematoxylin and eosin (A) and with TUNEL (terminal nucleotidyl transferase-mediated nick-end labeling) (B) in a prepubertal mouse that received cyclophosphamide 200 mg/kg 2 days earlier. Apoptosis in the granulosa cells surrounding the central oocytes is more evident on TUNEL than on hematoxylin and eosin staining. (C) Mature mouse femur stained with hematoxylin and eosin. (D) Detail of the growth plate section (with computerized measurements). (E) Detail of the growth plate section stained with TUNEL, showing apoptosis.

    With permission, from Detti L, Uhlmann RA, Zhang J, et al. Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril 2014; 101(4): 1157–1164. doi:10.1016/j.fertnstert.2013.12.028

  • Figure 2
    Figure 2

    Antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels and total follicle counts at age 56 days (A) and 92 days (B) in mice that had received cyclophosphamide (CTX) alone, CTX plus goserelin, or neither drug (controls) at age 18 days. Goserelin temporarily protected the ovaries, but the protection waned over time (*P < .05).

    With permission, from Detti L, Uhlmann RA, Zhang J, et al. Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril 2014; 101(4): 1157–1164. doi:10.1016/j.fertnstert.2013.12.028

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects